These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38270172)

  • 1. Impact of Meningococcal ACWY Vaccination Program during 2017-18 Epidemic, Western Australia, Australia.
    Ewe K; Fathima P; Effler P; Giele C; Richmond P
    Emerg Infect Dis; 2024 Feb; 30(2):270-278. PubMed ID: 38270172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Manifestations and Public Health Response for Outbreak of Meningococcal W Disease, Central Australia, 2017.
    Sudbury EL; O'Sullivan S; Lister D; Varghese D; Satharasinghe K
    Emerg Infect Dis; 2020 Jul; 26(7):1355-1363. PubMed ID: 32568047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Blain AE; Reese HE; Marjuki H; Topaz N; Mbaeyi S; McNamara LA
    Vaccine; 2021 Dec; 39(52):7541-7544. PubMed ID: 34802785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from a community vaccination programme to control a meningococcal disease serogroup W outbreak in remote South Australia, 2017.
    Flood L; McConnell M; Molchanoff L; Dodd Z; Sisnowski J; Fidock M; Miller T; Borresen K; Vogt H; Lane A
    Western Pac Surveill Response J; 2021; 12(1):26-31. PubMed ID: 34094620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015-2016.
    Campbell H; Edelstein M; Andrews N; Borrow R; Ramsay M; Ladhani S
    Emerg Infect Dis; 2017 Jul; 23(7):1184-1187. PubMed ID: 28409739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.
    Parikh SR; Campbell H; Bettinger JA; Harrison LH; Marshall HS; Martinon-Torres F; Safadi MA; Shao Z; Zhu B; von Gottberg A; Borrow R; Ramsay ME; Ladhani SN
    J Infect; 2020 Oct; 81(4):483-498. PubMed ID: 32504737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
    Tzanakaki G; Cabrnochová H; Delić S; Draganescu A; Hilfanova A; Onozó B; Pokorn M; Skoczyńska A; Tešović G
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301186. PubMed ID: 38173392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
    Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
    Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.